Mark Nishihara, MD
Internal Medicine · Aiea, HINPI 1134330491
Payments from drug & device makers
Across 618 payments — averaging $15.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Novo Nordisk$967
- Lilly USA, LLC$893
- Boehringer Ingelheim$870
- AstraZeneca$811
- Amarin Pharma, Inc.$744
- plus $3K from 23 others
What the payments were for
- Consulting fees$1752%
- Food & beverage$9,24398%
- Education$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 105 | $1,783 |
| Novo Nordisk | 71 | $967 |
| Lilly USA, LLC | 73 | $893 |
| Boehringer Ingelheim | 51 | $870 |
| AstraZeneca | 46 | $811 |
| Amarin Pharma, Inc. | 31 | $744 |
| GSK | 69 | $693 |
| Bayer | 27 | $442 |
| Pfizer | 17 | $348 |
| Kowa Pharmaceuticals America, Inc. | 40 | $345 |
| Merck | 14 | $257 |
| Teva Pharmaceuticals USA, Inc. | 16 | $227 |
| AbbVie(2 entities) | 7 | $164 |
| Dexcom, Inc. | 4 | $93 |
| Sanofi-aventis U.S. LLC | 7 | $91 |
| Arbor Pharmaceuticals, Inc. | 6 | $88 |
| Novartis | 5 | $86 |
| Smith+Nephew | 1 | $79 |
| Genentech USA, Inc. | 4 | $76 |
| Abbott | 4 | $73 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| Exact Sciences | 2 | $54 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $36 |
| Inspire Medical Systems, Inc. | 2 | $35 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Johnson & Johnson | 2 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$175
How this compares
$9,444 in reported general payments places this provider in the 90th percentile of 655 internal medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 97 | $145,268 |
| OzempicSemaglutide | 58 | $91,562 |
| JanuviaSitagliptin Phosphate | 35 | $39,932 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $38,882 |
| EliquisApixaban | 39 | $34,992 |
| MounjaroTirzepatide | 25 | $32,658 |
| Atorvastatin Calcium | 788 | $21,785 |
| VascepaIcosapent Ethyl | 22 | $19,546 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $12,224 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $9,390 |
| Losartan Potassium | 347 | $7,312 |
| Simvastatin | 299 | $6,524 |
| Wixela InhubFluticasone Propion/Salmeterol | 27 | $5,498 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,150 |
| Olmesartan Medoxomil | 62 | $5,008 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $870 | $145,26897 claims |
| Novo NordiskOzempic | $967 | $91,56258 claims |
| MerckJanuvia | $257 | $39,93235 claims |
| GSKTrelegy Ellipta | $693 | $38,88252 claims |
| PfizerEliquis | $348 | $34,99239 claims |
| Lilly USA, LLCMounjaro | $893 | $32,65825 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $91 | $9,39012 claims |
| AstraZenecaSymbicort | $811 | $5,15016 claims |
| AbbVieSynthroid | $164 | $1,47225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 655 internal medicine providers in Hawaii.
Other internal medicine in Aiea
- Alan OkiAiea$13K
- Joel KobayashiAiea$11K
- Roy EbisuAiea$11K
- Francis ButoAiea$10K
- Stephen MiyasatoAiea$10K
- Michael SavonaWailuku$520K
- Scott StromattKamuela$385K
- Keith WooHonolulu$106K
- Ronald PerryHonolulu$102K
- Laurie TomHonolulu$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.